SAN MARINO, Calif., April 4 /PRNewswire/ -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today the establishment of its main corporate headquarters in San Marino, California. The specialty pharmaceutical company has been granted Orphan Drug Status by the FDA for its lead product Rexin-G(TM), an innovative anti-cancer agent that seeks out and destroys metastatic disease. Rexin-G(TM) has been tested in a wide variety of cancer types, including pancreatic cancer, breast cancer, colon cancer, uterine cancer, laryngeal cancer, smooth muscle cancer (leiomyosarcoma) and skin cancer (malignant melanoma).
*(PHOTO: Send2Press.com/mediadesk/0406-EpeiusOFC_72dpi.jpg)
*(Photo Caption: Artist rendering of proposed renovated San Marino headquarters.)
*(LOGO: Send2Press.com/mediadesk/logo-epeius_72dpi.jpg)
Rexin-G(TM) is currently in clinical trials for metastatic pancreatic cancer at Mayo Clinic, Rochester, Minnesota, USA and is available for all solid tumors through an expanded access program in Manila, Philippines. The new headquarters in San Marino is located on the prestigious Huntington Drive and will integrate corporate offices, medical laboratories, and a Clinical Research Unit in appealing garden setting.
Founded in the year 2000 by an inspired physician and an intrepid biophysicist at the University of Southern California, Epeius Biotechnologies consolidates a decade of biomedical research that began with gene discovery at Childrens Hospital Los Angeles, was translated into medical delivery at the USC Keck School of Medicine, progressed to clinical development at the USC Norris Comprehensive Cancer Center, and conducted landmark clinical trials as a freestanding biopharmaceutical company.
In a statement to the press, Dr. Erlinda Maria Gordon, M.D., founder and Chairman of the Board stated: “In the years to come, we hope and expect that the scientific and clinical accomplishments of Epeius Biotechnologies Corporation will become a source of pride and joy for the entire San Marino community.”
For more information visit: http://www.epeiusbiotech.com
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
Epeius Biotechnologies
CONTACT: Dr. Frederick L. Hall, President and CEO of EpeiusBiotechnologies Corporation, +1-626-441-6695, or fax, +1-626-441-6692,info@epeiusbiotech.com; Plain text copy:http://Send2Press.com/mediadrome/2006-04-0404-004.txt
